Compare Scope Fluidics SA with Similar Stocks
Dashboard
Unrated Stock - No Analysis Available
Stock DNA
Pharmaceuticals & Biotechnology
PLN 433 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.81
-30.83%
2.91
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2026)
Net Profit:
-10 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-36.51%
0%
-36.51%
6 Months
-20.84%
0%
-20.84%
1 Year
-30.23%
0%
-30.23%
2 Years
-40.0%
0%
-40.0%
3 Years
-2.12%
0%
-2.12%
4 Years
-9.09%
0%
-9.09%
5 Years
-24.05%
0%
-24.05%
Scope Fluidics SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.59%
EBIT Growth (5y)
-220.63%
EBIT to Interest (avg)
-19.85
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.94
Sales to Capital Employed (avg)
0.00
Tax Ratio
27.74%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
28.67%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.52
EV to EBIT
-5.58
EV to EBITDA
-5.85
EV to Capital Employed
9.18
EV to Sales
254.51
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-164.66%
ROE (Latest)
-30.83%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
0.00
0.70
-100.00%
Operating Profit (PBDIT) excl Other Income
-10.70
-7.60
-40.79%
Interest
0.00
1.60
-100.00%
Exceptional Items
1.50
0.40
275.00%
Consolidate Net Profit
-10.10
-8.60
-17.44%
Operating Profit Margin (Excl OI)
-354,218.80%
-12,510.00%
-34,170.88%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is -100.00% vs 600.00% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is -17.44% vs -30.30% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
0.10
0.10
Operating Profit (PBDIT) excl Other Income
-45.10
-30.90
-45.95%
Interest
0.20
0.20
Exceptional Items
1.60
1.30
23.08%
Consolidate Net Profit
-46.40
65.40
-170.95%
Operating Profit Margin (Excl OI)
-472,270.00%
-247,679.40%
-22,459.06%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 0.00% vs -80.00% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -170.95% vs 447.87% in Dec 2024
About Scope Fluidics SA 
Scope Fluidics SA
Pharmaceuticals & Biotechnology
Scope Fluidics SA is a Poland-based company engaged in the biotechnology. The Company focuses on diagnostic and med-tech solutions. It develops disposable microfluidic systems for the collection of micro-samples of blood, as well as storage of reagents for diagnostic markers. Its projects include PCR ONE system that delivers the bacterial and viral pathogen detection, and BacterOMIC system that delivers information on bacterial susceptibility to antibiotics and on the resistance mechanisms. The Company provides access to laboratories and workshops for developed projects, as well as administrative facilities and services, including financing. In addition, it cooperates with doctors, medical personnel, project managers, engineers and academics.
Company Coordinates 
Company Details
Duchnicka 3, bud. 16, wejscie A , WARSZAWA None : 01-796
Registrar Details
Footer loading






